Drug

Anti-PD-1/IL-15 Fusion Protein JMT108 clinical trials

Also written JMT108.

studies test it: 6
open now: 6
in phase 3: 0
first study started: 2025

Keep track of what changes. Save the Anti-PD-1/IL-15 Fusion Protein JMT108 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

JMT108: 3

Combined with it in one product

SYS6090 Injection + Bevacizumab Injection: 1
SYS6090 Injection +SYS6043 Injection +Bevacizumab Injection: 1
SYS6090 (Fixed Dose Level A) + bevacizumab: 1
SYS6090 (Fixed Dose Level B ) + bevacizumab: 1
SYS6090 + pemetrexed + platinum-based chemotherapy: 1
SYS6090 + paclitaxel + platinum-based chemotherapy: 1
SYS6090 + docetaxel: 1
SYS6090 + pemetrexed + bevacizumab + platinum-based chemotherapy: 1

Studies by the year they started

6 studies that test it; most in 2025 (3)

Studies that test Anti-PD-1/IL-15 Fusion Protein JMT108, by start year
Year	Studies
2025	3
2026	3

By phase

A phase 1/2 study counts in both.

Phase 1: 6
Phase 2: 5

What it is tested for

Each study’s main condition, where its own words name it.

Carcinoma, Hepatocellular: 1
Colorectal Neoplasms: 1
Carcinoma, Non-Small-Cell Lung: 1
Melanoma: 1
Neoplasms: 1

Who runs them

Industry 6 · Other 0

Shanghai JMT-Bio Inc. (3) · CSPC Megalith Biopharmaceutical Co.,Ltd. (2) · Conjupro Biotherapeutics, Inc. (1)

Often tested with

Tested in the same studies.

Bevacizumab (3) · Anti-B7-H3/TOP1i Antibody-drug Conjugate SYS6043 (1) · Sintilimab (1) · Regorafenib (1) · Pemetrexed (1) · Paclitaxel (1) · Docetaxel (1) · Anti-EGFR Antibody-drug Conjugate CPO301 (1)

Studies

Open first, then newest update. How each study uses Anti-PD-1/IL-15 Fusion Protein JMT108 is read from its arms, and is right about nine times in ten.